Literature DB >> 20206156

Monoclonal gammopathy in a tertiary referral hospital.

Waleed Tamimi1, Ahmad Alaskar, Mohammed Alassiri, Waleed Alsaeed, Saud A Alarifi, Faris Q Alenzi, Dunia Jawdat.   

Abstract

OBJECTIVE: Monoclonal gammopathies reflect conditions of plasma B-cell disorders. Our objective was to identify the prevalence and types of these gammopathies in our population.
METHODS: A 10year retrospective study was conducted. Serum and/or urine protein electrophoresis were performed on 6624 samples. Positive bands were further tested by immunofixation (IFE).
RESULTS: Homogenous bands were detected in 7% of the patients. IFE method confirmed 6.3% in which 59% were males and 41% were females. The mean age was 64.7 for females and 66.5 for males. The sensitivity and specificity were 91% and 99% respectively. The most common protein was IgG kappa 41%, followed by IgG lambda 19%. Sixty-eight percent of these patients had monoclonal gammopathy of undetermined significance and 14.6% had multiple myeloma.
CONCLUSION: The majority of the studied population had MGUS. This observation is in concord with other western populations. The sensitivity and specificity of protein electrophoresis is diagnostically and reasonably acceptable. 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206156     DOI: 10.1016/j.clinbiochem.2010.02.009

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  2 in total

1.  Monoclonal gammopathies in a Moroccan military hospital.

Authors:  Z Ouzzif; K Doghmi; S Bouhsain; A Dami; S El Machtani; S Tellal; N Messaoudi; M Mikdame; A El Maataoui
Journal:  Rheumatol Int       Date:  2011-09-01       Impact factor: 2.631

2.  [Descriptive cross-sectional study assessing the clinical and paraclinic profiles of monoclonal gammopathies in an agricultural region of Souss-Massa, Morocco].

Authors:  Aissam El Maataoui; Aadil Taoufiq; Salma Fares; Kaouthar Sokori
Journal:  Pan Afr Med J       Date:  2022-01-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.